Andre Goy, MD, MS

Andre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.

Andre Goy, MD, MS, discusses the paradigm shift in the treatment of patients with mantle cell lymphoma that has occurred over the past decade.

Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, MS, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, MS, chief, discusses the results of the multicenter FLYER trial in patients with diffuse large B-cell lymphoma.

Andre Goy, MD, MS, discusses treatment approaches for older patients with mantle cell lymphoma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the significance of becoming a National Cancer Institute-designated cancer center.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment considerations in mantle cell lymphoma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment options for patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses future treatment approaches in patients with mantle cell lymphoma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the molecular features of mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses challenges in the treatment of patients with mantle cell lymphoma.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the cost of chimeric antigen receptor (CAR) T-cell therapy.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the FDA approval of the rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy.

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center at Hackensack University Medical Center, discusses the affordability of cancer treatment breakthroughs such as chimeric antigen receptor T-cell therapy.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of bendamustine plus cytarabine as treatment for patients with mantle cell lymphoma.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses recent therapeutic advancements in the field of mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy reported with ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the impact lenalidomide (Revlimid) has had on the treatment paradigm of mantle cell lymphoma (MCL).

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the takeaways for community oncologists in the field of mantle cell lymphoma (MCL).